AstraZeneca PLC
AstraZeneca PLC (AZN) is a large‑cap global biopharmaceutical company focused on discovery, development and commercialisation of prescription medicines, with particular strength in oncology, cardiovascular, renal & metabolic (CVRM), and respiratory therapies. The firm combines a broad marketed portfolio with an active R&D pipeline and significant investment in biologics and precision medicines. For investors, key considerations include steady revenue from established drugs, growth driven by newer oncology and rare‑disease launches, and continued R&D spend that can both support long‑term value and create near‑term earnings variability. The company operates globally, exposing it to different regulatory and pricing environments and currency movements. AstraZeneca has historically paid dividends, but dividend levels and share price can fluctuate with trial outcomes, patent expiries and competition. This summary is educational only — not personalised investment advice — and investors should weigh growth potential against clinical, regulatory and commercial risks.
Why It's Moving
AstraZeneca Ditches Nasdaq for NYSE in Bold Listing Shake-Up
- Simplifies share structure by shifting from two-for-one ADSs to direct ordinary shares, enhancing trading consistency worldwide.
- Retains AZN ticker on NYSE to preserve investor familiarity and liquidity amid the exchange switch.
- Recent Barclays upgrade to Overweight with higher price target underscores confidence in pharma growth prospects despite the transition.
AstraZeneca Ditches Nasdaq for NYSE in Bold Listing Shake-Up
- Simplifies share structure by shifting from two-for-one ADSs to direct ordinary shares, enhancing trading consistency worldwide.
- Retains AZN ticker on NYSE to preserve investor familiarity and liquidity amid the exchange switch.
- Recent Barclays upgrade to Overweight with higher price target underscores confidence in pharma growth prospects despite the transition.
When is the next earnings date for AstraZeneca PLC (AZN)?
AstraZeneca PLC is expected to report its next earnings on February 10, 2026 before market open, covering the fourth quarter of fiscal 2025. The company has not yet officially confirmed this date, but it is projected based on historical earnings release patterns. Analysts are currently forecasting earnings per share of $1.09 for the period. This earnings release will be followed by a conference call to discuss the company's financial performance and guidance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AstraZeneca's stock with a target price of $114.08, indicating strong growth potential.
Financial Health
AstraZeneca is performing well with strong profits, cash flow, and revenue, indicating solid financial stability.
Dividend
AstraZeneca's projected dividend yield of 4.63% makes it a reasonable choice for dividend-seeking investors. If you invested $1000 you would be paid $46.30 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring AZN
Pharma Onshoring Boom: Investment Risk Considerations
AstraZeneca is building a major new manufacturing plant in the U.S., responding to policy pressures for domestic production. This signals a broader trend of onshoring pharmaceutical manufacturing, creating opportunities for companies that build and equip these advanced facilities.
Published: October 10, 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: September 23, 2025
Explore BasketObesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: September 10, 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: August 3, 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: July 2, 2025
Explore BasketMade in the UK
Diversify your portfolio with some of Britain's most established companies. Our analysts have carefully selected these UK powerhouses that span multiple industries from banking to pharmaceuticals, energy to consumer goods.
Published: May 10, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketUK-US Trade Deal
These carefully selected UK stocks could benefit from the newly announced US-UK trade agreement, the first under Trump's second administration. Our professional analysts have identified companies with potential upside as tariffs are cut on British exports like steel, aluminum, and more.
Published: May 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline drives growth
AstraZeneca’s R&D pipeline, especially in oncology and precision medicines, can support future revenue, though trial outcomes and approvals are uncertain.
Global footprint matters
Wide geographic reach diversifies revenue but brings exposure to regulatory, pricing and currency risks that can affect results.
Innovation and spending
Heavy investment in biologics and new modalities underpins long‑term potential while creating earnings variability in the near term.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
